Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECVAX-NEO1 in solid tumors
NCT05354323Phase 1Active, not recruiting
- Sponsor
- NEC OncoImmunity
- Start
- May 2022
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NECVAX-NEO1 in non-small cell lung cancer (NSCLC), melanoma, urothelial carcinoma (UC) and 2 more, sponsored by NEC OncoImmunity. Primary endpoint: Treatment-emergent adverse events at 36 weeks. Started May 2022; status: active, not recruiting.
02
Drugs
NECVAX-NEO1
03
Conditions
non-small cell lung cancer (NSCLC)melanomaurothelial carcinoma (UC)renal cell carcinoma (RCC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05354323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354323.